Emory University

Atlanta, GA

Atlanta Clinical and Translational Science Institute (Atlanta-CTSI)

Principal Investigator
David S. Stephens, M.D.

Participating Institutions:

Abstract (provided by applicant):

The Atlanta Clinical and Translational Science Institute (Atlanta-CTSI) is led by Emory University, along with partners Morehouse School of Medicine, Georgia Institute of Technology, and Children's Healthcare of Atlanta. These institutions are already partners in healthcare, education, and cutting-edge, interdisciplinary research that will be propelled by the Atlanta-CTSI.

The established partnerships and diverse faculty enable the Atlanta-CTSI to combine strong clinical, translational, training and basic discovery programs at Emory with the health disparities, training and community outreach focus of Morehouse School of Medicine together with the engineering and bioinformatics achievements of Georgia Tech and the excellence in pediatrics of Children's Healthcare of Atlanta. Collaborations with the private non-profit Georgia Bio organization and the Georgia Research Alliance, the state-sponsored academic-industry partnership, create additional synergies that foster and accelerate development and application of new and emerging technologies. Finally the Atlanta-CTSI creates dynamic community, public health, informatics, and population studies programs through partnerships and collaborations with Kaiser Permanente of Georgia (KPGA), the Centers for Disease Control and Prevention, and the Atlanta Veterans Affairs Medical Center.

Photo: Nana Gletsu Miller, Ph.D., is an assistant professor in the Department of Surgery at Emory University School of Medicine. Her research program studies patients undergoing weight loss and the effects of excess adipose tissue on obesity-related diseases. She is performing an ELISA assay to measure concentrations of adipose tissue cytokines in plasma samples obtained from these patients. (Photo courtesy of Emory University) - Download Photo (1.9MB JPG)

Johns Hopkins University

Baltimore, MD

Johns Hopkins Institute for Clinical and Translational Research

Principal Investigator
Daniel E. Ford, M.D., M.P.H.

Participating Institutions:

Abstract (provided by applicant):

The new Johns Hopkins Institute for Clinical and Translational Research will synergize many existing translational research efforts across the Johns Hopkins Schools of Engineering, Medicine, Nursing, and Public Health. The Institute will create new opportunities to partner with patient communities and for profit organizations that are dedicated to moving new medical interventions into practice. Incorporating new partners for clinical research among community hospitals and primary care organizations will also be a priority. The Institute will provide comprehensive training programs for clinical and translational research that will be targeted for the full range of learners. Clinical and translational researchers will be supported by new programs in biostatistics; innovative methodology; patient recruitment; navigating through regulatory offices; clinical research management systems; bioinformatics; data safety and monitoring programs; building community bridges; research ethics consultations; and the Accelerated Translational Incubator Program (pilot program). New translational cores in drug, device and vaccine development, proteomics, genetics, and imaging will create new translational research teams. Basic science and translational science forums will be utilized to create and support new research teams that span the translational pathway.

(Photo courtesy of Johns Hopkins University) - Download Photo (2.2MB JPG)

University of Chicago

Chicago, IL

University of Chicago CTSA

Principal Investigator
Julian Solway, M.D.

Participating Institutions:

Abstract (provided by applicant):

The ultimate goals of the University of Chicago CTSA program are : 1) to train scientists and health care providers at the University, partner institutions, and community to determine the molecular underpinnings of disease and disease predisposition in any individual patient; 2) to develop, test, implement, and make readily available to community residents personalized therapies directed toward those individual underpinnings; and 3) to do this in a way that is rigorous, valid, efficient, ethical, and respectful of our community's needs and values. In a robust alliance with ANL, IIT, and two large health care organizations, the UC CTSA will undertake three bold new steps that will transform clinical and translational research: 1) Creation of an Institute for Translational Medicine, a new University-wide structure to collect, integrate, and disseminate the intellectual, organizational, and resource infrastructure needed to promote and support multidisciplinary translational research collaborations; 2) Synergistic research interaction with a new Urban Health Initiative which, through partnership with community stakeholders, aims to improve community health care access and quality, to build health literacy and trust throughout the community, to enhance a translational research program informed by and responsive to the needs of the community, and so to reduce health disparities; and 3) Establishment of a new academic Committee on Clinical and Translational Science and of multiple novel training programs to encourage and develop careers in clinical and translational research, intended for high school students through university faculty and across the entire translational research spectrum. CTSA investigators will employ a systems medicine approach to leverage their particular expertise in social science, genetic medicine, and integrative therapeutics.

University of Iowa

Iowa City, IA

University of Iowa's Institute for Clinical and Translational Science

Principal Investigator
Gary W Hunninghake, M.D.

Participating Institutions:

Abstract (provided by applicant):

The University of Iowa's Institute for Clinical and Translational Science includes 39 established University centers and institutes representing all 11 UI colleges. Examples include the UI Hospitals and Clinics' General Clinical Research Center; the Holden Comprehensive Cancer Center at the UI; the Law, Health Policy, and Disability Center; the Prairielands Addiction Technology Transfer Center; the Northern Plains Native American Health Disparities Center; and the Upper Midwest Public Health Training Center. Partnerships with the University of Arizona and Iowa State University add richness and diversity to the Institute's efforts. The Institute will energize strong UI research programs in areas like optical science, oral and maxillofacial implants, nanotechnology, and advanced imaging, and nurture newer initiatives like community-based research. The Institute's statewide network of community practitioners, hospitals, and health organizations will help identify areas for further study, improve public perception of clinical research, and make cutting-edge research, discoveries and treatments available to patients wherever they live. Looking even further ahead, the Institute's masters and Ph.D. degree programs in clinical and translational science will prepare tomorrow's researchers. CTSA support will advance research at the UI in innumerable ways.

Photo: Michael Hildebrand studying gene therapies for hearing loss. (Photo courtesy of University of Iowa) - Download Photo (493KB JPG)

University of Michigan

Ann Arbor, MI

Michigan Institute of Clinical and Health Research

Principal Investigator
Daniel J Clauw, M.D.

Participating Institutions:

Abstract (provided by applicant):

The Michigan Institute of Clinical and Health Research creates partnerships among the relevant units of the University, the NIH, external industry partners, and the community. The overwhelming majority of UM schools, colleges, and institutes are participating, including: the top-ranked Schools of Business, Dentistry, Medicine, Nursing, Social Work, and Public Health; the Colleges of Engineering, Pharmacy, Literature, and Science and Arts; the Division of Kinesiology; the Institute of Social Research; and the Life Sciences Institute. The University-owned Health System, which includes integrated outpatient and inpatient facilities, is contributing significantly to a strong partnership with the UM CTSA site. In addition to the grant resources, the institution is contributing substantial in-kind support, cost-sharing, support of pilot and recruitment programs, and renovation costs, a more than 1:1 match of NIH dollars. The University of Michigan CTSA program includes an Education Program that reaches a wide spectrum of audiences: from undergraduates to mid-career faculty, from basic scientists to population researchers, from staff to community members.

Photo: Basic and clinical researchers in the Allergy and Clinical Immunology Division at the University of Michigan Medical School form collaborative relationships with other units to speed discoveries to patients. (Photo courtesy of University of Michigan) - Download Hi-Res (1.1MB JPG) Photo

University of Texas Southwestern Medical Center

Dallas, TX

North and Central Texas Clinical and Translational Science Initiative

Principal Investigator
Milton Packer, M.D.

Participating Institutions:

Abstract (provided by applicant):

The North and Central Texas Clinical and Translational Science Initiative will be led by the University of Texas Southwestern Medical School at Dallas and will include schools of allopathic and osteopathic medicine, dentistry, nursing, pharmacy, public health, engineering and computer science, which have already formed relationships supported by a Roadmap K12 award. A new Department of Clinical Sciences, which is supported by faculty from all participating schools, will serve as the academic home for the CTSA site. Existing infrastructure and support include: a substantial financial commitment of participating institutions to the Initiative; more than 200 established clinical and translational investigators who will act as faculty and mentors; and a large and medically diverse patient base cared for by established hospitals.

Photo: Dr. Milton Packer, chairman of clinical sciences at UT Southwestern Medical Center, is principal investigator for the UT Southwestern-led North and Central Texas Clinical and Translational Science Initiative. (Photo courtesy of UT Southwestern Medical Center) - Download Hi-Res (1.7MB JPG) Photo

University of Washington

Seattle, WA

Institute of Translational Health Sciences

Principal Investigator
Mary (Nora) L. Disis, M.D.

Participating Institutions:

Proposed American Indian and Alaska Native Network Sites:

Abstract (provided by applicant):

The Institute of Translational Health Sciences represents a consortium of six University of Washington (UW) health science professional schools with multiple partners that cover 12 performance sites, involve 67 scientific key personnel and connect researchers to over 150 centers. In addition, the Institute of Translational Health Sciences proposes to integrate major research and clinical institutions across a five-state region: Washington, Wyoming, Alaska, Montana, and Idaho (WWAMI) via ongoing clinical and research collaboration pathways that are part of the WWAMI program led by the UW School of Medicine.

A unique feature of this CTSA site is its community engagement plan which considers diversity across race, ethnicity, culture, rural and urban locations, geography, health status and health service delivery with a targeted program for Alaska Natives and American Indians. The Institute of Translational Health Sciences will support an integrated ethics program linking adult and pediatric medical centers and the community. An additional unique feature is the site's advanced capability for therapeutic product development and clinical testing that will enhance future health care throughout the region. The Institute of Translational Health Sciences will foster new health sciences interactions across the sites through a variety of technology, education, and research support cores. The Institute will guide, support and facilitate translational research efforts that focus on expanded information collection, sharing and analysis, innovative scientific technologies, and critical support services aimed at accelerating health sciences research.

Photo: Dr. Mary "Nora" Disis, right, and researcher Vivian Goodell are conducting research to develop a cancer vaccine that would work like immunizations against infectious diseases. (Photo by Paul Joseph Brown, courtesy of the Seattle Post-Intelligencer)

University of Wisconsin

Madison, WI

Institute for Clinical and Translational Research (ICTR)

Principal Investigator
Marc K. Drezner, M.D.

Participating Institutions:

Abstract (provided by applicant):

The University of Wisconsin-Madison, through its new Institute for Clinical and Translational Research (ICTR), will address how to translate biomedical discoveries into practices that improve health. The ICTR will take a new approach to research by producing interdisciplinary research scientists who can address health problems along a continuum--from basic laboratory investigations through clinical trials in patients and into population health studies in communities. The Institute will provide researchers an array of tools and will create feedback systems to ensure that research is relevant and addresses the health care needs of populations in Wisconsin.

The Institute will be the hub of a network that fans across the university and extends around the state. People based at five schools on campus and several hospitals in Madison will be involved as will experts at academic campuses on all points of the Badger State compass. New and existing statewide partnerships will be enhanced. Physicians and public health workers in towns and communities throughout the state will be essential players.

Vanderbilt University

Nashville, TN

Vanderbilt Institute for Clinical and Translational Research (VICTR)

Principal Investigator
Gordon R. Bernard, M.D.

Participating Institutions:

Abstract (provided by applicant):

The Vanderbilt Institute for Clinical and Translational Research (VICTR) will be created to focus on both bench-to-bedside, and bedside-to-practice translation. Vanderbilt intends to remove impediments and release investigators from administrative burdens, produce inspired personnel trained in the bi-directional process of translational research, foster innovation by stimulating contributions from collaborators, and enrich the translational research environment with extensive state-of-the art informatics tools as well as expert biostatistics support. The proposed institute will leverage Vanderbilt's existing NIH-funded General Clinical Research Center (GCRC), which has been an established center generating clinical research for 50 years. The funds will also be used to establish a Community Engagement and Research program, which leverages the very strong ties of Vanderbilt to the community. Important to the overall success of the program is a focused partnership with Meharry Medical College. Also involved within Vanderbilt is the Institute for Medicine and Public Health as well as the Schools of Medicine, Nursing, Law, Business, Engineering, Peabody College of Education and Human Development, the College of Arts and Sciences, and the Kennedy Center for Research on Human Development.

Photo: Sandy Yoder, a senior research specialist, works in Vanderbilt University Medical Center's Pediatric Infectious Diseases Lab. She uses liquid nitrogen to keep vials at 320 degrees below zero. Yoder is putting away influenza samples obtained in vaccine trials at Vanderbilt. (Photo courtesy of Vanderbilt University) - Download Hi-Res (623KB JPG) Photo

Washington University

St. Louis, MO

CTSA at Washington University

Principal Investigator
Kenneth S. Polonsky, M.D.

Participating Institutions:

Abstract (provided by applicant):

The CTSA at Washington University (WU) in St. Louis will be implemented by creating a new Institute of Clinical and Translational Sciences designed to conceptually and operationally reinvent and reinvigorate clinical and translational research and research training. The Institute incorporates existing programs (GCRC, K12, K30, and T32) and WU's new BioMed 21 strategic initiative in multidisciplinary, collaborative research in genome sciences, biological imaging, and clinical investigation. It also involves an unprecedented level of partnership with other academic, health care, community and scientific institutions in the St. Louis area. Partners include BJC HealthCare; Saint Louis University School of Public Health, Graduate School and Doisy College of Health Sciences; University of Missouri St. Louis College of Nursing; Southern Illinois University Edwardsville School of Nursing; and St. Louis College of Pharmacy; key organizations promoting community health as well as biomedical and pharmaceutical companies in the St. Louis area. The Institute of Clinical and Translational Sciences will oversee 15 key programs, each designated to facilitate the safe and ethical conduct of research in humans.

Photo: Samuel Klein, M.D., professor of medicine, and Jennifer McCrea, research coordinator, offer health and nutrition tips to 10 year old Van Carter at the Adams Park Elementary School Wellness Fair. Dr. Klein will be the director of the CTSA Clinical Interactions Resources Core at the Washington University Institute of Clinical and Translational Sciences. (Photo courtesy of Washington University) - Download Hi-Res (3.3MB JPG) Photo

Weill Cornell Medical College

New York, NY

CTSA at Weill Cornell Medical College

Principal Investigator
Julianne L. Imperato-McGinley, M.D.

Participating Institutions:

Abstract (provided by applicant):

The Clinical and Translational Science Center (CTSC) - comprising public/private institutions on the Upper East Side of Manhattan - is a unique and diverse biomedical complex, providing investigators with state-of-the-art resources for conducting clinical/translational research.

Weill Cornell Medical College of Cornell University, the lead institution, serves as conduit through which technological resources and educational programs are efficiently shared and managed. Neighboring institutions contribute significantly to the CTSC. Hospital for Special Surgery, a leader in investigating musculoskeletal and autoimmune diseases, is one of two medical institutions designated by NIH as a Core Center for Skeletal Integrity. Memorial Sloan-Kettering Cancer Center is a cancer center where state-of-the-art basic science research flourishes side-by-side with clinical investigation and treatment at Memorial Hospital. Cornell University Cooperative Extension, NYC, engaged in research addressing the needs of a changing New York for over fifty years, will be the linchpin for community outreach. Hunter College Gene Center's Research Center for Minority Institutions recruits and nurtures minority talent and has established an effective electronic network with minority scientists nationwide. Hunter College School of Nursing, training nurses from a diverse urban population, will participate in community outreach and education in underserved areas.

Photo: Dr. Nasser Altorki, director of the Division of Thoracic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center, confers with a colleague about a CT scan of a patient's chest. (Photo courtesy of Weill Cornell Medical College) - Download Hi-Res (215KB JPG) Photo

Duke University

Durham, NC

Clinical Translational Science Institute (CTSI)

Principal Investigator
Robert M. Califf, M.D.
E-mail: calif001@mc.duke.edu

Abstract (provided by applicant):

Duke University proposes to create a Clinical Translational Science Institute (CTSI). This institute will accomplish four specific aims: 1) create an institute that will transform how fundamental discoveries are translated into improved medical care by supporting creative translational research teams. The institute will provide leadership and resources for original translational and clinical research, and it will develop and perform studies regarding novel methods and approaches to translational and clinical science; 2) create an environment in which trainees at all levels, including medical and nursing school students, physical therapists, pharmacologists, house staff, fellows, graduate students, junior faculty, and career transition faculty can be trained in translational and clinical research. The training will be built on the principle that a rich clinical and translational research environment will provide Duke University trainees with models and opportunities for success; 3) integrate translational and clinical science by fostering collaboration among Duke University's departments, institutes, centers, and schools, using human resources supported by modern bioinformatics and a new clinical research unit designed to integrate intensive measurements of biological processes; 4) and develop a community model for understanding how to translate the findings of research from bench to bedside, to populations using advanced informatics and health services delivery methods. The Duke University CTSI will be founded on three entities, or pillars, including Duke University Translational Research Institute (DTRI), Duke University Clinical Research Institute (DCRI), and Duke University Center for Community Research (DCCR). These three entities will bring together and expand existing programs, and will be designed to emphasize the continuities along the spectrum of research that begins in a basic science laboratory and concludes with novel therapies that change outcomes for individual patients. These three pillars—DCRI, DTRI, and DCCR—will be administratively joined into the new Duke University Clinical and Translational Science Institute (Duke University CTSI), the core of this application. This new institute will link with other key programs, including Duke University Comprehensive Cancer Center, Duke University School of Nursing, and Duke University Institute for Genome Sciences and Policy, to create a comprehensive home for clinical and translational researchers. The creation of the CTSI is relevant to public health as it will create an environment that will foster speedier delivery of new interventions and healthcare practices to the community.

Photo: Scientists at Duke University Medical Center (Martin Tornai, Ph.D. shown here) have created a new breast scanner that will dramatically improve their ability to visualize small tumors while also reducing radiation exposure to one-tenth that of normal mammograms. Moreover, the new device does not compress the breast, as do traditional mammograms. (Photo courtesy of Duke University Medical Center) - Download Photo (16KB JPG)

Mayo Clinic College of Medicine

Rochester, MN

Center for Clinical and Translational Research (CCTR)

Principal Investigator
Robert A. Rizza, M.D.

Abstract (provided by applicant):

The goal of the Mayo Clinic CTSA application is to present Mayo's vision for the integration and expansion of our innovative clinical and translational research activities, so that a highly functional academic home for clinical and translational research is developed at the Mayo Clinic. This new Center for Clinical and Translational Research (CCTR) will be founded on Mayo Clinic's long-standing excellence in and commitment to clinical and translational research, which includes the support of key infrastructure and a commitment to career development. To achieve this goal, Mayo will take a comprehensive approach to the key elements of the CTSA RFA and focus on enhancing: 1) clinical research core resources that provide innovative tools to investigators; 2) career development and education programs that prepare the next generation of investigators; 3) compliance and regulatory affairs support that ensures patient safety and privacy, and customer service-oriented approaches to support investigative teams; 4) community affairs support to enhance participation, diversity and community support for clinical and translational research; 5) collaboration with industry and clinical practices to translate research discoveries into routine clinical practice; and 6) continued and expanded institutional support that includes an "academic home" for clinical and translational research. Mayo Clinic also proposes a consolidated governance plan that incorporates strong data-driven evaluation of each CCTR element and the program as a whole. In principle, the CTSA program is consistent with the historical, conceptual, and philosophical underpinnings of Mayo Clinic, and this application clearly articulates how the overarching and transformative goals of the CTSA program can be met at Mayo. Additionally, the CCTR has the "institutional will" and is culturally empowered to execute this plan. Thus, Mayo is ready to implement the CTSA program aggressively and rapidly; the Mayo Clinic CCTR will be a highly functional and successful "flagship" site for the CTSA program as it emerges from the NIH Roadmap. To summarize, the Mayo Clinic Center for Clinical and Translational Research (CCTR) will bring together all the resources of the five schools within the Mayo Clinic College of Medicine, and more than 100 years of scientific and medical research expertise, to discover innovative new methods that will speed the translation of research results into therapies, tools, and patient care practices that impact all members of the local and national communities. This vision is entirely consistent with the stated mission of the Mayo Clinic to provide the best care to every patient, every day, through integrated clinical practice, education, and research.

Oregon Health & Science University

Portland, OR

Oregon Clinical and Translational Science Institute (OCTSI)

Principal Investigator
Eric Orwoll, M.D.
E-mail: orwoll@ohsu.edu

Abstract (provided by applicant):

Biomedical research institutions in Oregon are outstanding, and are prepared for a major expansion in clinical/translational investigation. The university proposes to form the Oregon Clinical and Translational Science Institute (OCTSI). The OCTSI will fundamentally change biomedical research to create a vibrant academic home for clinical/translational investigation. It will leverage existing strengths and remove barriers to the pace and growth of research. At the heart of the OCTSI is a robust partnership between Oregon Health & Science University (OHSU) and Kaiser Permanente's Center for Health Research (KPCHR) that brings together a strong biomedical research university and an innovative practice-based research center associated with a large patient population. The collaboration provides unique opportunities for expansion across the spectrum of human investigation, and sets the stage for major advances in human health. Transformation of clinical and translational research in Oregon is enhanced by: robust institutional support for the OCTSI, manifest by significant administrative change as well as the commitment of substantial financial and space resources; academic faculties at OHSU and KPCHR that fully support the OCTSI initiative and the development of a strong, multidisciplinary OCTSI leadership team; merging of resources to form a coordinated infrastructure for clinical/translational research; and strong ties to the community and the involvement of the region in the human research agenda. We have identified three major goals for the OCTSI, and propose far-reaching, explicit, and feasible approaches to achieve them. The university will 1) create an academic home specifically devoted to the discipline of clinical/translational research; 2) nurture a new cadre of highly-trained, interdisciplinary investigators through a strong, diverse educational curriculum; and 3) create a "research commons"—a coordinated infrastructure of core research tools that greatly expands research opportunities and provides a unified, effective means for their access. There are particular opportunities to accelerate progress in pediatric and child health, community based research, and human genetics.

Rockefeller University

New York, NY

Rockefeller University Center for Clinical and Translational Sciences

Principal Investigator
Barry Coller, M.D.
E-mail: collerb@rockefeller.edu

Abstract (provided by applicant):

The Rockefeller University Hospital, a GCRC awardee since 1963, has been the continuous "home" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, will integrate and expand Rockefeller University's scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new center will transform clinical and translational research by encouraging new studies, enhancing and centralizing the support structures required to conduct studies with scientific rigor, and ensuring an absolute commitment to the protection of human subjects and participant safety. The key elements in the transformation will be: 1) a new governance structure reflecting the NIH cooperative agreement (U54) "assistance" mechanism; 2) creation of a new K12 Clinical Research Scholars Program offering master's and Ph.D. level degrees to complement the current Clinical Scholars Program; 3) infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of good clinical practice (GCP), including biomedical informatics, biostatistics, bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office; and 4) development of innovative and novel core methodologies related to dendritic cell therapy; vaccine development for HIV, hepatitis C, and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology, and novel diagnostic, preventive, and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The center will be an active member of the national CTSA consortium, offering the consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will eagerly adopt the best practices identified by the consortium and adhere to the standards set by the consortium.

University of California, Davis

Davis, CA

Clinical and Translational Science Center (CTSC)

Principal Investigator
Lars F. Berglund, M.D., Ph.D.
E-mail: lars.berglund@ucdmc.ucdavis.edu

Abstract (provided by applicant):

The University of California, Davis (UC Davis) is proposing to create a Clinical and Translational Science Center (CTSC) that will transform its medical research enterprise into a highly effective "open" academic home for clinical and translational research by building on three key assets: 1) a long-standing commitment as a land-grant university to serve the geographically dispersed and ethnically diverse populations of inland and northern California with a health care system enabled by one of the broadest and most extensive telecommunications programs in the world; 2) the collaborative culture of UC Davis, which has one of the most extensive and interdisciplinary life science environments in the country; and 3) an established CTSC pilot facility—the UC Davis Clinical Research Investigator Services Program (CRISP) that serves as the physical home for clinical and translational research, and for faculty training and career development. CRISP is a fundamentally important CTSC testing ground where many perceived CTSC barriers have been explored and solutions have been tested. Through CRISP, UC Davis has completed the planning phase for the CTSC. In the organizational structure of the UC Davis CTSC, considerable attention is paid to create an organization that is: 1) responsive and familiar to investigators; 2) flexible; 3) well linked to university leadership, to participating academic units, and to the community; and 4) focused on the goal of reducing barriers and facilitating the translation of research gains into medical practice. Key features are: an education program focused on "team science;" extensive collaborations across UC Davis colleges and centers; introduction of catalyst functions such as collaborative research facilitators and translational postdoctoral fellowships; dissemination through tele-technology; flexible use of resources for patient-oriented research; and a community engagement program emphasizing trust and respect. The CTSC is under the leadership of two co-principal investigators, Drs. Berglund M.D., Ph.D., (P.I.) and Joseph M.D., Ph.D. (co-P.I.), supported by a team of directors and co-directors that oversees each of the nine CTSC programs, and a comprehensive committee structure, designed to firmly anchor the CTSC with institutional leadership, faculty, trainees, and the community. The UC Davis CTSC will be implemented through a carefully designed, collaborative plan, and the activity will be guided through continuous evaluations and corrections.

Photo: A cadre of leading scientists and physicians will be overseeing the new UC Davis Clinical and Translational Science Center. A few program leaders include: Ann Bonham, Ph.D., executive associate dean for research and education; Lars Berglund, M.D., Ph.D., assistant dean of clinical research and director of the new center; and Fitz-Roy Curry, associate dean for research. - Download Hi-Res (1MB JPG) Photo

University of California, San Francisco

San Francisco, CA

Clinical and Translational Science Institute (CTSI)

Principal Investigator
Joseph M. McCune, M.D., Ph.D.
E-mail: mmccune@gladstone.ucsf.edu

Abstract (provided by applicant):

Despite explosive gains in our understanding of the basic mechanisms of human disease, meaningful translation of this knowledge to the treatment and prevention of disease has moved slowly. To accelerate the pace at which discoveries in basic science can serve the health of our patients and community, the University of California, San Francisco (UCSF) intends to establish a Clinical and Translational Science Institute (CTSI). Its mission will be to create a comprehensive, integrated academic home that promotes research and education in clinical and translational science at UCSF, at affiliated institutions, and in participating communities. Its goals are: 1) to support, enhance, and integrate existing training programs, increasing the number of trainees from diverse disciplines and improving the quality of their training in clinical and translational research methods; 2) to support, improve, and integrate existing infrastructure to enhance the design and implementation of clinical and translational studies, fostering collaborations to achieve a diverse spectrum of high-quality, original research; 3) to enhance career development of clinical and translational researchers by providing mentoring and opportunities to catalyze original research, and by changing the academic culture to appropriately reward multidisciplinary collaborative work; and 4) to create a "virtual home" providing contemporary communications to simplify collaboration, to provide an optimal informatics matrix for conducting innovative research, and to nurture the growth of clinical and translational science. To reach these goals, UCSF is transforming its clinical and translational research organization to establish 13 interrelated programs that will provide the training, services, and opportunities needed. These programs are led by senior scientists drawn from diverse disciplines in each of UCSF's four health science schools—dentistry, medicine, nursing, and pharmacy—and its graduate division. The plans reflect input from more than 200 interested, energetic, and committed participants from throughout the community, including most of UCSF's academic leaders. These individuals worked collaboratively to ensure inclusion, transparency, and flexibility in the design and planned implementation of the CTSI. UCSF believes that this infusion of new energy and resources will create and sustain a rich environment for innovative research and drive the realization of UCSF's full potential to educate and to support the work of clinical and translational scientists. If so, biomedicine will be advanced and the health of our patients and the community will benefit.

Photo: Joseph DeRisi, Ph.D., in his lab at the University of California, San Francisco. (Photo by Felix Aburto, courtesy of UCSF) - Download Hi-Res (2.6MB JPG) Photo

University of Pennsylvania

Philadelphia, PA

Institute for Translational Medicine and Therapeutics (ITMAT)

Principal Investigator
Garret A. FitzGerald, M.D.
E-mail: garret@spirit.gcrc.upenn.edu

Abstract (provided by applicant):

The Clinical and Translational Research Award (CTSA) has been greeted enthusiastically by the University of Pennsylvania (Penn). A strategic plan had identified clinical and translational research as a priority, leading to formation of the Institute for Translational Medicine and Therapeutics (ITMAT) in January 2005. ITMAT anticipated many aspects of the CTSA—amongst them, inclusion of the GCRC, dedicated "dry" and "wet" bench space for translational research, and a robust educational program, configured on a Master in Translational Research (MTR). This CTSA application prompted intra- and inter-institutional consideration of how to build on this achievement. This has forged a transformational alliance between Penn, the Children's Hospital of Philadelphia (CHOP), the Wistar Institute (WI) and the University of the Sciences in Philadelphia (USP). Faculty from nine of the 12 schools at Penn and from the partner institutions are represented in leadership roles in the response to this CTSA. ITMAT, designated as the "academic home" for clinical and translational research, has been broadened to serve a transinstitutional role. Its structure has been transformed to foster interdisciplinary science from discovery of new molecules through to the study of drug action in large populations. This has been accomplished by developing interdisciplinary centers, related cores, innovative interdisciplinary programs of research, and strategies to engage and inform communities and their physicians. A particular emphasis has been placed on training and innovative programs, which cover the entire career span, engaging undergraduate students through to mature clinicians. The proposal includes the flexible use of the MTR and new tracks in the Master in Clinical Epidemiology (MSCE) with the M.D., Ph.D., V.M.D., M.S.N., D.M.D., and M.B.A. degrees; the set-aside of places for medical school entrants pursuing M.D.-MTR/MSCE degrees; and the flexible use of diverse faculty tracks at Penn and CHOP to broaden physician engagement in research. These initiatives will be pursued in partnership with industry (e.g., GSK, Oracle), the State of Pennsylvania (BioAdvance), the FDA, and a national network of institutions holding CTSAs. An elaborate and diversified approach to tracking the productivity of this program has been developed and will be integrated into a national plan with similar centers. In summary, this initiative has fostered: 1) an integrated strategy to clinical and translational research by Penn, CHOP, the WI and USP; and 2) the transformation of ITMAT. This will permit the development of interdisciplinary structures designed to foster and facilitate research and education in this emerging discipline.

Photo: Biomedical research technician pipetting sample for translational therapeutic study at the University of Pennsylvania School of Medicine. (Photo by Dan Naylor, courtesy of the University of Pennsylvania School of Medicine) - Download Hi-Res (5.4MB JPG) Photo

The Clinical and Translational Science Award was submitted jointly by the University of Pennsylvania, The Children's Hospital of Philadelphia, the Wistar Institute, and the University of the Sciences in Philadelphia. The CTSA grant will foster research across the lifespan for many disorders, such as sleep disorders.

Photo: Caitlyn Regan, participating in a sleep study at The Children's Hospital of Philadelphia's sleep lab, with Carole Marcus, M.D.,co-principal investigator of the Clinical and Translational Science Award, and Director of Children's Hospital's Sleep Center and Robert Heinle, M.D., pulmonary fellow. (Photo courtesy of Children's Hospital of Philadelphia) - Download Hi-Res (1.5MB JPG) Photo

University of Pittsburgh

Pittsburgh, PA

Clinical and Translational Science Institute (CTSI)

Principal Investigator
Steven E. Reis, M.D.
E-mail: reisse@upmc.edu

Abstract (provided by applicant):

As one of the nation's leading academic research centers, the University of Pittsburgh has both an opportunity and an obligation to take the inherent risks associated with reengineering a successful research enterprise and to undertake a transformative initiative that will result in the development and advancement of clinical and translational science as a distinct discipline in western Pennsylvania. The university is committed to transforming its culture, environment, and structure to achieve this goal by forming the Clinical and Translational Science Institute (CTSI). The CTSI will serve as the integrative academic home for clinical and translational scientists across the university's six health sciences schools; Carnegie Mellon University; the University of Pittsburgh Medical Center (UPMC)—one of the nation's largest and most financially successful academic health care systems—and the region. The CTSI's primary focus is to develop, nurture, and support a cadre of clinical and translational scientists by building on the university's existing clinical research training programs to establish a comprehensive program with activities ranging from early research exposure for high school students to advanced doctoral programs. Through "integration and innovation," the CTSI will excel in the development of new biomedical knowledge and the translation of that knowledge from the basic and preclinical research settings to individuals, communities, and health practice. The Children's Hospital of Pittsburgh's General Clinical Research Center (GCRC) and the four sites of the University of Pittsburgh GCRC will be reengineered, integrated, and augmented by new CTSI community-based and minority-health-focused centers to develop efficient, accessible, and widely used participant and clinical interaction resources. The CTSI Center for Clinical and Translational Informatics, which is developing translational research informatics tools for the NCI Cancer Biomedical Informatics Grid Initiative, will infuse informatics tools into the entire lifecycle of clinical research studies and develop an online collaborative research community. Innovative, interdisciplinary research initiatives will be developed through the 10 CTSI resource cores, and translated to health practice via a novel CTSI community partnership program and through centralization of UPMC's extensive clinical networks. The resulting transformations in the institution, scientists, research, and health practice will improve health locally, regionally, and nationally.

University of Rochester

Rochester, NY

University of Rochester Clinical and Translational Science Institute (UR CTSI)

Principal Investigator
David S. Guzick, M.D., Ph.D.
E-mail: david_guzick@urmc.rochester.edu

Abstract (provided by applicant):

The University of Rochester Clinical and Translational Science Institute (UR CTSI) will be created as the academic home for clinical and translational science, providing a centralized, integrated infrastructure. Under a system of governance in which the UR CTSI program director has authority over space, faculty, budgets, and other resources related to the CTSI, and in which much of the current GCRC budget is distributed to CTSI in support of these key functions, the university plans to transform the two distinct research fields of clinical and translational science into a single new discipline. The goals of this discipline include the creation of new knowledge and techniques to diagnose, prevent, and treat human disease, and the establishment of an environment that catalyzes their application to clinical practice in the community. To achieve these goals, the university proposes specific aims involving: novel methodologies; pilot studies; upgraded biomedical informatics, epidemiology, research design, ethics, and regulatory support; community engagement; new technology and resource cores; new educational and training programs; an upstate New York consortium; and rigorous evaluation and measurement of performance outcomes. Strategic planning for the UR CTSI has been underway for several years. Evidence of institutional support includes commitment to a new 150,000-square-foot Clinical and Translational Science Building (CTSB) in which faculty conducting clinical and translational research will be brought together with students and trainees in existing and new degree-granting programs; with supporting regulatory and administrative functions; and with faculty working in collaborative disciplines such as biostatistics, epidemiology, and biomedical informatics. The director and co-directors of the UR CTSI will integrate the clinical and translational science functions contained in the CTSB with those functions located at other campus locations, such as functional genomics, other translational resources, and the General Clinical Research Center (GCRC). As an integral part of the CTSI, the GCRC will move into a newly-renovated 10,500-square-foot facility across the street from the CTSB, with enhanced functionality and subject access. As well, the UR CTSI will create two-way synergies with local community groups such as the school system, faith community, businesses, foundations, and other upstate New York institutions. Further, the UR CTSI will enable the sharing of data across disciplines and across institutions while ensuring the privacy and confidentiality of human subjects. In summary, by coalescing and integrating new facilities with enhanced infrastructure, community and state-wide partnerships, a strong foundation of existing research and training, and a fundamentally reorganized administrative structure, the CTSI will transform the conduct of clinical and translational science at UR and contribute nationally to the forging of this new discipline.

Photo: John Treanor, M.D., professor of medicine and a director of the University of Rochester's Vaccine and Treatment Evaluation Unit, is a leading investigator of vaccines for bird flu and other diseases. He also will be active in the Rochester Clinical and Translational Research Institute. (Photo courtesy of University of Rochester) - Download Hi-Res (3.2MB JPG) Photo

University of Texas Health Science Center at Houston

Houston, TX

Center for Clinical and Translational Sciences (CCTS)

Principal Investigator
Frank C. Arnett, M.D.
E-mail: frank.c.arnett@uth.tmc.edu

Abstract (provided by applicant):

The University of Texas Health Science Center at Houston (UTHSC-H) proposes to establish a Center for Clinical and Translational Sciences (CCTS) at the Texas Medical Center (TMC) in Houston. Participating faculty and trainees in the CCTS will include those from the UTHSC-H component degree-granting schools, including its Medical School, School of Public Health, Graduate School of Biomedical Sciences, School of Health Information Sciences, School of Nursing, Dental Branch, and Brown Foundation Institute of Molecular Medicine (IMM), as well as collaborating faculty/facilities The University of Texas M.D. Anderson Cancer Center (MDACC), which also is located in the TMC. The academic "home" for the CCTS will be in 11,422 square feet of newly renovated space at the UT Medical School, which is physically joined to Memorial Hermann-Texas Medical Center and serves as its partner and primary teaching hospital. The CCTS "home" will administer all aspects of the CCTS; and provide space and resources for faculty and trainees, along with expertise in study design, biostatistics, regulatory issues, ethics, bioinformatics, funding of pilot and feasibility studies, provision of resources, protected time for clinical and translational faculty and trainees, and interactions/collaborations with the various communities and industry. For participant and clinical interactions resources (PCIR), the CCTS will subsume the UTHSC-H General Clinical Research Center (GCRC) at Memorial Hermann, the satellite UTHSC-H GCRC at Brownsville, Texas, and, in part, the MDACC Clinical and Translational Research Center, to enhance research productivity and efficiency. In its educational component, the CCTS will subsume, in part, the current Center for Clinical Research and Evidence-Based Medicine, which has developed and currently provides formal classes, mentoring, and a Master of Clinical Research (MCR) degree at UTHSC-H, and an active NCRR K30 award at MDACC. Also proposed in the application is a novel T32 application offering combinations of master's and doctoral degrees in community health sciences, biomedical sciences and/or biomedical informatics—primarily for pre-doctoral students—and a K12 application for post-doctoral trainees and junior faculty. The CCTS also will subsume core translational laboratories, including a genotyping/sequencing core, a biomarkers core offering DNA microarray, RT-PCR and proteomics services, an immune monitoring core, an MRI core, and a biobanking core. A CCTS "think tank" composed of highly accomplished translational and clinical investigators, basic scientists and educators, and community representatives, will come together as an "engine for innovation" to bring forward and recommend the application of novel and emerging scientific information, methods, and technologies to research into human health and diseases across specialties, disciplines, and communities.

Photo: Dianna Milewicz, M.D., Ph.D., professor and director of medical genetics at The University of Texas Medical School at Houston, directs research in the Genetics Core Lab. The lab will help facilitate more rapid research results at UT-Houston's Center for Clinical and Translations Sciences. (Photo by Ester Fant, courtesy of The University of Texas Health Science Center at Houston) - Download Hi-Res (1.7MB JPG) Photo

Yale University

New Haven, CT

Yale Center for Clinical Investigation (YCCI)

Principal Investigator
Robert S. Sherwin, M.D.
E-mail: robert.sherwin@yale.edu

Abstract (provided by applicant):

The Yale Center for Clinical Investigation (YCCI) was created to provide a "home" for training the next generation of clinical investigators. Key programmatic goals are to: 1) attract highly talented students and junior faculty across medicine, nursing, public health, biological sciences, and biomedical engineering; train them in the use of state-of-the-art research tools; give them the skills to work within complex research teams; and support their professional development; and 2) foster the translation of disease-related discoveries from the laboratory into the community by: stimulating the creation of interdisciplinary teams; making available state-of-the-art core facilities and expanded biostatistical and bioinformatics resources; establishing organizational and regulatory infrastructure for clinical studies; and forging a dynamic new partnership that will integrate community leaders, physicians, and health centers. Participating institutions include the Schools of Medicine, Nursing, Public Health, the Department of Biomedical Engineering, and graduate programs in biological and biomedical sciences. The investigative medicine program (IMP) is central to YCCI's education and training efforts. It is a unique doctoral program that offers Ph.D. degrees in health sciences research to highly qualified M.D. fellows embarking on careers in translational or clinical research. IMP will be expanded with CTSA support to include nursing, public health, biological sciences, and M.D.-Ph.D. students. YCCI has also created a Society of YCCI Faculty Mentors who will participate actively in the training and nurturing of the students and junior faculty members identified as YCCI Clinical Scholars. Pilot and feasibility grants will be awarded for: 1) junior faculty; 2) interdisciplinary translational teams; 3) new technologies; and 4) community-based projects. YCCI will cluster research cores around common themes, including: imaging; specimen analysis; physiology; cognition and behavior; drug development; and cell therapy. A new office of research services will provide facilities for "one-stop" shopping for regulatory, biostatistical, bioinformatics, recruitment, and other support services. YCCI will have an office to coordinate the university's efforts to address health issues facing our community. The university's decision to immediately provide substantial support to establish the YCCI reflects its strong commitment to an innovative redesign of our clinical and translational research activities.

Photo: Charles J. Lockwood, M.D., chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, consults with a patient on an ultrasound with Sifa Turan, former postdoctoral fellow and sonographer at Yale Ob/Gyn. (Photo courtesy of Yale University) - Download Hi-Res (1.5MB JPG) Photo